Impact of photodynamic therapy on quality of life of patients with age-related macular degeneration in Korea
- PMID: 20700801
- DOI: 10.1007/s10384-010-0825-x
Impact of photodynamic therapy on quality of life of patients with age-related macular degeneration in Korea
Abstract
Purpose: To assess quality of life (QOL) changes in patients with age-related macular degeneration (AMD) before and after treatment with photodynamic therapy (PDT).
Methods: In 625 patients with AMD, the EuroQol Health Questionnaire (EQ-5D) for general health status and the Visual Function Questionnaire (VF-4D) for vision-related reading ability, independence, and fear for the future were used and the results compared between within 1 week before PDT and 1 year after PDT. Subscale QOL changes were also scored with the Korean versions of EQ-5D and VF-4D.
Results: EQ-5D scores of male patients were higher than those of female patients (P < 0.05), and scores of unilateral patients were higher than those of bilateral patients (P < 0.001). Among all patients, 41.2% had a higher EQ-5D score after PDT. The mean differences between before and after treatment, estimated by three different models, the Korean model, the UK model, and the Japanese model, were all statistically significant (P < 0.001). Utility measured by the VF-4D score after PDT increased by 16.1% (P < 0.001), and subscale utilities indicated significant improvements in fear for the future (21.1%), reading ability (16.6%-14.5%), and independence (11.6%).
Conclusions: PDT for patients with AMD improved both general health-related QOL and vision-related QOL, as well as subscale scores, as evaluated by EQ-5D and VF-4D.
Similar articles
-
Full macular translocation (FMT) versus photodynamic therapy (PDT) with verteporfin in the treatment of neovascular age-related macular degeneration: 2-year results of a prospective, controlled, randomised pilot trial (FMT-PDT).Graefes Arch Clin Exp Ophthalmol. 2009 Jun;247(6):745-54. doi: 10.1007/s00417-009-1050-5. Epub 2009 Feb 12. Graefes Arch Clin Exp Ophthalmol. 2009. PMID: 19214552 Clinical Trial.
-
Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab.Ophthalmology. 2013 Jan;120(1):160-8. doi: 10.1016/j.ophtha.2012.07.027. Epub 2012 Sep 23. Ophthalmology. 2013. PMID: 23009891 Clinical Trial.
-
Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.Clin Ther. 2007 Sep;29(9):2096-106; discussion 2094-5. doi: 10.1016/j.clinthera.2007.09.001. Clin Ther. 2007. PMID: 18035208
-
Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.Curr Drug Targets. 2011 Feb;12(2):149-72. doi: 10.2174/138945011794182746. Curr Drug Targets. 2011. PMID: 20887246 Review.
-
Preserving vision with verteporfin photodynamic therapy.Hosp Med. 2004 Jan;65(1):39-43. doi: 10.12968/hosp.2004.65.1.2417. Hosp Med. 2004. PMID: 14964795 Review.
Cited by
-
Predictors of health-related quality of life in Chinese patients receiving treatment for neovascular age-related macular degeneration: a prospective longitudinal study.BMC Ophthalmol. 2020 Jul 16;20(1):291. doi: 10.1186/s12886-020-01561-3. BMC Ophthalmol. 2020. PMID: 32677913 Free PMC article.
-
Chinese Version of the EQ-5D Preference Weights: Applicability in a Chinese General Population.PLoS One. 2016 Oct 6;11(10):e0164334. doi: 10.1371/journal.pone.0164334. eCollection 2016. PLoS One. 2016. PMID: 27711169 Free PMC article.
-
A review of generic preference-based measures of health-related quality of life in visual disorders.Value Health. 2012 Jan;15(1):118-27. doi: 10.1016/j.jval.2011.08.002. Epub 2011 Oct 1. Value Health. 2012. PMID: 22264979 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources